MannKind’s AFREZZA vs. Pfizer’s Exubera: Will Inhaled Insulin Be Different This Time?
January 21, 2010 by tim · Leave a Comment
With an FDA decision pending on Mannkind Corporation’s AFREZZA (TM) (insulin human (rDNA origin) Inhalation Powder – formerly named AFRESA ) and the recent failure of the first inhaled insulin to receive FDA approval, we thought it would be helpful to provide an analytical approach to this emerging health technology. For those who are unfamiliar [...]
